SKYE logo

Skye Bioscience, Inc. Stock Price

NasdaqGM:SKYE Community·US$41.2m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 10 Fair Values set on narratives written by author

SKYE Share Price Performance

US$1.33
-3.38 (-71.76%)
US$1.33
-3.38 (-71.76%)
Price US$1.33

SKYE Community Narratives

There are no narratives available yet.

Snowflake Analysis

Flawless balance sheet with moderate risk.

5 Risks
0 Rewards

Skye Bioscience, Inc. Key Details

US$0

Revenue

US$0

Cost of Revenue

US$0

Gross Profit

US$42.4m

Other Expenses

-US$42.4m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
-1.37
0%
0%
0%
View Full Analysis

About SKYE

Founded
n/a
Employees
16
CEO
Punit Dhillon
WebsiteView website
skyebioscience.com

Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Recent SKYE News & Updates

Is Skye Bioscience (NASDAQ:SKYE) In A Good Position To Invest In Growth?

Sep 06
Is Skye Bioscience (NASDAQ:SKYE) In A Good Position To Invest In Growth?

Recent updates

No updates